SOURCE: TapImmune Inc.

August 05, 2009 06:00 ET

TapImmune Announces Acquisition of Additional Technology

Company Completes Technology and IP Acquisition From The UBC Pursuant to an Option Agreement

BELLEVUE, WA--(Marketwire - August 5, 2009) - TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the acquisition of three follow-on inventions and IP relating to its key TAP technology from The University of British Columbia.

"These inventions add depth to our pipeline and strengthen the intellectual property position of our TAP technology platform," said Denis Corin, President of TapImmune Inc.

The three patent applications involve the enhancement of antigen presentation in both cancer and infectious disease models.

TapImmune, Inc. has an extensive and diverse patent portfolio covering the use of TAP (transporters associated with antigen processing) and related products to enhance the effectiveness of vaccines against infectious diseases and for use as immunotherapeutic agents against cancers. This patent portfolio includes three issued United States patents, as well as numerous pending United States and world-wide patents and patent applications.

TapImmune's patent portfolio is a valuable asset to the company and its shareholders, and is designed to protect and extend its core technical developments by creating multiple layers of protection for potential new product candidates to treat emerging diseases.

About TapImmune

TapImmune is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.

The Company's vaccine has shown, in preclinical tests, effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. TapImmune is preparing GLP manufactured materials for the commencement of toxicology studies on the AdhTAP vaccine, leading to the initiation of a Phase I clinical trial application. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times.

Additional information on the Company can be found on its web site

Safe Harbor Statement

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at The Company assumes no obligation to update the forward-looking statements.

Contact Information